Prediction of beneficial effect of beta blocker treatment in severe ischaemic cardiomyopathy: assessment of global left ventricular ejection fraction using dobutamine stress cardiovascular magnetic resonance.
Kaandorp
T A M
TA
Lamb
H J
HJ
Bax
J J
JJ
Boersma
E
E
Viergever
E P
EP
van der Wall
E E
EE
de Roos
A
A
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D004280:Dobutamine; D005240:Feasibility Studies; D006333:Heart Failure / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D018810:Magnetic Resonance Angiography / Q000379:methods; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy*; D011412:Propanolamines / Q000627:therapeutic use*; D013318:Stroke Volume / Q000187:drug effects; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis* / Q000209:etiology
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D004280:Dobutamine